^
    4d
    MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, University of Arkansas | Initiation date: Apr 2026 --> Jul 2026
    Trial initiation date
    |
    clonoSEQ
    |
    lenalidomide • Darzalex (daratumumab) • melphalan • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    10d
    M22-574: A Phase 3 study of Etentamig vs Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (3L+ RRMM Monotherapy Study) (2023-506668-15-00)
    P2/3, N=147, Active, not recruiting, AbbVie Deutschland GmbH & Co. KG | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    bortezomib • Xpovio (selinexor) • carfilzomib • dexamethasone • pomalidomide • Empliciti (elotuzumab) • etentamig intravenous (ABBV-383 IV)
    11d
    Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Feb 2026 --> May 2026
    Trial initiation date
    |
    Tecvayli (teclistamab-cqyv)
    11d
    MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma (clinicaltrials.gov)
    P2, N=46, Active, not recruiting, Pfizer | N=34 --> 46
    Enrollment change
    |
    lenalidomide • dexamethasone • Elrexfio (elranatamab-bcmm) • Ogsiveo (nirogacestat)
    12d
    LINKER-MM8: A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) (clinicaltrials.gov)
    P2/3, N=1570, Not yet recruiting, Regeneron Pharmaceuticals
    New P2/3 trial
    |
    lenalidomide • bortezomib • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Lynozyfic (linvoseltamab-gcpt)
    12d
    LINKER-SMM1: A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, Regeneron Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Lynozyfic (linvoseltamab-gcpt)
    13d
    M25-586: A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant (2025-520897-21-00)
    P2/3, N=24, Not yet recruiting, AbbVie Deutschland GmbH & Co. KG
    New P2/3 trial • Adverse events
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • etentamig intravenous (ABBV-383 IV)
    15d
    Immunoglobulin supplementation and longer dosing intervals reduce risk of infections in patients with RRMM treated with teclistamab. (PubMed, Blood Cancer J)
    Importantly, longer dosing intervals reduced infection rates for all-grade infections (from 6.08 infections per patient-year during weekly dosing to 2.25 infections per patient-year during bimonthly dosing) and for severe infections (from 0.81 infections per patient-year during weekly dosing to 0.1 per patient-year during bimonthly dosing). These results underline the importance of the assessment of annualized infection rates to reflect the true infectious burden in patients who were treated with BCMA-directed BsAbs.
    Journal
    |
    B2M (Beta-2-microglobulin)
    |
    Tecvayli (teclistamab-cqyv)
    15d
    ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia (clinicaltrials.gov)
    P1/2, N=38, Not yet recruiting, Mayo Clinic
    New P1/2 trial
    |
    etentamig intravenous (ABBV-383 IV)
    17d
    EMN39: A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab Versus continued Daratumumab, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients (2024-519827-16-00)
    P2/3, N=713, Recruiting, European Myeloma Network B.V., Emn Trial Office S.r.l. Impresa Sociale
    New P2/3 trial
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • Lynozyfic (linvoseltamab-gcpt)
    17d
    EMN37: Study for frail patients with newly diagnosed multiple myeloma treated with Daratumumab in combination with Teclistamab and Talquetamab. (2024-520433-76-00)
    P1/2, N=150, Recruiting, European Myeloma Network B.V., Emn Trial Office S.r.l. Impresa Sociale
    New P1/2 trial
    |
    Darzalex (daratumumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    17d
    TMP-23062025-2: An open label, phase I/II study investigating the safety and efficacy of the bispecific T-cell engaging antibody cizutamig (BCMAxCD3) in patients with immune-mediated inflammatory diseases the SPLENDID Trial (2025-522857-20-00)
    P1/2, N=12, Recruiting, Fraunhofer Institute For Translational Medicine And Pharmacology ITMP
    New P1/2 trial